Program
Please note that this special conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. The conference content will be recorded and made available as an on-demand program after the conference.
CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
Sunday, September 28
- Welcome and Opening Keynote Lecture
- Plenary Session 1: Revolutionizing Early Diagnosis and Prevention
monday, September 29
- Plenary Session 2: Spotlight on New Drug Development
- Plenary Session 3: Biology of Pancreatic Cancer Progression
- Plenary Session 4: Harnessing the Immune System to Treat Pancreatic Cancer
tuesday, September 30
- Plenary Session 5: Translational Advances to Dissect Pancreatic Cancer Treatment Response
- Plenary Session 6: Tumor Heterogeneity and Evolution
- Plenary Session 7: New Therapeutic Strategies
wednesday, october 1
REGISTRATION
3-8 p.m.
WELCOME AND Keynote lectures
5-6:10 p.m.
- 5 p.m. | Welcome from Conference Cochairs
- 5:20 p.m. | Keynote Lecture
Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, Massachusetts - 5:50 p.m. | Rising Star Keynote
Ashley L. Kiemen, Johns Hopkins University of Medicine, Baltimore, Maryland
break
6:30-6:45 p.m.
plenary Session 1: Revolutionizing Early Diagnosis and Prevention
6:40-8:30 p.m.
Session Chair: Laura DeLong Wood, Johns Hopkins University School of Medicine, Baltimore, Maryland
- 6:45 p.m. | Opportunities with understanding early pancreatic cancer
Laura DeLong Wood - 7:10 p.m. | Elliot Fishman, Johns Hopkins University School of Medicine, Baltimore, Maryland
- 7:30 p.m. | Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 7:50 p.m. | Developing successful strategies for the early detection of pancreatic adenocarcinoma
Randall E. Brand, University of Pittsburgh, Pittsburgh, Pennsylvania
OPENING RECEPTION
8:30-10:30 p.m.
CONTINENTAL BREAKFAST
7-8 a.m.
cochair highlights
8-8:30 a.m.
Plenary Session 2: Spotlight on New Drug Development
8:30-10:15 a.m.
Session Chair: Eileen M. O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
- 8:35 a.m. | David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 8:55 a.m. | CRISPR-drug combinatorial screening identifies effective combination treatments for CDKN2A/MTAP-null PDAC
Kathleen M. Mulvaney, Virginia Polytechnic Institute and State University, Washington, DC - 9:15 a.m. | Kim A. Reiss, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
break
10:15-10:45 a.m.
PLENARY Session 3: Biology of Pancreatic Cancer Progression
10:45 a.m.-12:30 p.m.
Session Chair: Marina Pasca di Magliano, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
- 10:50 a.m. | Stress adaptation in pancreatic tumorigenesis
Elda Grabocka, Thomas Jefferson University, Philadelphia, Pennsylvania - 11:10 a.m. | Identifying immune vulnerabilities in pancreatic cancer
Dieter Saur, Technical University of Munich, Germany - 11:30 a.m. | Mutant GNAS drives an indolent phenotype in IPMN by modulating the glycome
Kathleen E. DelGiorno, Vanderbilt University School of Medicine, Nashville, Tennessee
lunch on own/free time
12:30-2:30 p.m.
Plenary Session Session 4: Harnessing the Immune System to Treat Pancreatic Cancer
2:30-4:15 p.m.
Session Chair: Gregory L. Beatty, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
- 2:35 p.m. | Cryptic antigens: Novel targets for TCR-based therapies in pancreas cancer
William Freed-Pastor, Dana-Farber Cancer Institute, Boston, Massachusetts - 2:55 p.m. | Modulating the immunosuppressive stroma: bringing antitumor immune cells back into the game
Debora Barbosa Vendramini Costa, Michigan State University, Detroit, Michigan
Additional speaker to be announced
Poster session a/reception
4:30-7 p.m.
CONTINENTAL BREAKFAST
7-8 a.m.
cochair highlights
8-8:30 a.m.
Plenary Session Session 5: Translational Advances to Dissect Pancreatic Cancer Treatment Response
8:30-10:15 a.m.
Session Chair: Manuel Hidalgo, Weill Cornell Medicine, New York, New York
- 8:35 a.m. | Eric A. Collisson, Fred Hutchinson Cancer Center, Seattle, Washington
- 8:55 a.m. | Pancreatic cancer phenotypes
Faiyaz Notta, UHN Princess Margaret Cancer Center, Toronto, ON, Canada - 9:15 a.m. | Targeting the oncogenic state of RAS: Lessons from tri-complex inhibitors
Mallika Singh, Revolution Medicines, Redwood City, California
break
10:15-10:45 a.m.
Plenary Session 6: Tumor Heterogeneity and Evolution
10:45 a.m.-12:15 p.m.
Session Chair: Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina
- 10:50 a.m. | Dana Pe’er, Memorial Sloan Kettering Cancer Center, New York, New York
- 11:10 a.m. | The “viral-like” behavior of pancreatic cancer
David T. Ting, Massachusetts General Hospital Cancer Center, Boston, Massachusetts - 11:30 a.m. | Deconstructing reciprocal tumour-host interactions in the pancreatic cancer microenvironment
Claus Jorgensen, Cancer Research UK Manchester Institute, Manchester, England
lunch on own
12:15-3:30 p.m.
Plenary Session 7: New Therapeutic Strategies
3:30-5:45 p.m.
Session Chair: Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts
- 3:35 p.m. | Targeting tumor-nerve interactions in pancreatic cancer
- William L. Hwang, Massachusetts General Hospital, Boston, Massachusetts
- 3:55 p.m. | Targeting crosstalking mechanisms supporting pancreatic cancer
Christopher J. Halbrook, University of California, Irvine, California - 4:15 p.m. | Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, Texas
poster session b/reception
5:30-8 p.m.
CONTINENTAL BREAKFAST
7-8:30 a.m.
Meet-the-Expert / Mentoring Roundtables Session
7:30-8:30 a.m.
No pre-registration is required for this session. Attendance is on a first-come, first-served basis. Participants may rotate to as many tables as they like during the session, providing the opportunity to network and interact with a diverse cadre of experts. Mentors and topics to be announced.
cochair highlights
8:30-9 a.m.
Plenary Session 8: Futuristic Goals in Multimodality Care
9-10:25 a.m.
Session Chair: Alice Wei, Memorial Sloan Kettering Cancer Center, New York, New York
- 9:05 a.m. | Vaccine therapy in pancreatic cancer
Kevin C. Soares, Memorial Sloan Kettering Cancer Center, New York, New York - 9:25 a.m. | Nina Niu Sanford, University of Texas Southwestern Medical Center, Dallas, Texas
- 9:45 a.m. | Neeha Zaidi, Johns Hopkins University School of Medicine, Baltimore, Maryland
break
10:25-10:45 a.m.
Plenary Session 9: to be announced
10:45 a.m.-12:15 p.m.
Departure
12:15 p.m.